

Request for Prior Authorization ANTIEMETIC-5HT3 RECEPTOR ANTAGONISTS/ SUBSTANCE P NEUROKININ PRODUCTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

FAX Completed Form To 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

Prescriber Help Desk 1.833.587.2012

IA Medicaid Member ID #	Patient name	DOB			
Patient address					
Provider NPI	Prescriber name	Phone			
Prescriber address Fax					
Pharmacy name	Address	Phone			
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax NDC				

Prior authorization is required for preferred Antiemetic-5HT3 Receptor Antagonists/Substance P Neurokinin medications for quantities exceeding the dosage limits provided in parentheses. Payment for Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents beyond this limit will be considered on an individual basis after review of submitted documentation.

Prior authorization will be required for all non-preferred Antiemetic-5HT3 Receptor Antagonists/ Substance P Neurokinin medications beginning the first day of therapy. Payment for non-preferred medications will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent in this class. Note: Aprepitant (Emend®) will only be payable when used in combination with other antiemetic agents (5-HT3 medication and dexamethasone) for patients receiving highly emetogenic cancer chemotherapy.

Preferred		Non	<u>Preferred</u>			
Emend 80mg capsules (8)			Akynzeo (2)		Sancuso Patch	
Emend 125mg capsules (4)			\square Aloxi 0.25mg/5mL (4 vials)		🗌 Varubi	
Ondansetron 4mg tablets (60)		$\Box A$	Anzemet 50mg & 100mg tablets (5)		🗌 Zuplenz	
Ondansetron 8mg tablets (60)			Anzemet 100mg/5mL (4 vials)			
Ondansetron $2mg/mL (4 - 20mL vials)$		L vials) $\square A$	Anzemet 12.5mg/0.625mL (8 ampules)			
Ondansetron $2mg/mL(8 - 2mL \text{ vials})$		vials) 🗌 🗌 A	Aprepitant			
Ondansetron ODT 4mg tablets (60)		(60) \square (60)	\Box Granisetron 1mg tablets (8)			
Ondansetron ODT 8mg tablets (60)		· · —	Granisetron 1mg/mL (8 vials)			
Ondansetron oral solution 4mg/5mL Granisetron 4mg/4mL (2 vials)						
(50mL/mont			C X	,		
·	,					
	Strength	Dosage Instruc	ctions Quantity	Days Sup	ply	
Diagnasia						
Diagnosis:						
0						
	ing for therapy exce	edina dosage lir	nits:			
	ing for therapy exce	eding dosage lir	nits:			
	ing for therapy exce	eeding dosage lir	nits:			
Medical reason	ing for therapy exce of Non-Preferred d					
Medical reason Reason for use		rug requiring prid	or approval:			

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.